The relationship between acute toxicity in rats (LD50 values) and indicators of potential health hazards in humans was investigated, based on a chemical population-based paradigm (i.e. the “chemical diversity approach”). These structure–activity relationship-based analyses indicate that high toxicity in rats (i.e. a low LD50 value) is not a good predictor of health effects in humans. In fact, it was found that high acute toxicity to minnows, as well as toxicity to cultured cells, showed significantly greater associations with the potential for health effects than rat LD50 values.
OECD (2001). Harmonised Integrated Classification System for Human Health and Environmental Hazards of Chemical Substances and Mixtures. ENV/JM/MONO(2001)6, 247 pp. Paris, France: Organisation for Economic Co-operation and Development.
American Chemistry Council (2003). Summary of Voluntary Testing Framework for High Production Volume Chemicals. Website http://www.american-chemistry.com (Accessed 11.1.05).
5.
BrownV.J. (2003). REACHing for chemical safety. Environmental Health Perspectives111, A767–A769.
6.
McKinneyI.D., RichardA., WallerC., NewmanM.C., & GerberickF. (2000). The practice of structure–activity relationships (SAR) in toxicology. Toxicological Sciences56, 8–17.
HulzebosE.M., & PosthumusR. (2003). (Q)SARs: gatekeepers against risk on chemicals?SAR and QSAR in Environmental Research14, 285–316.
9.
CroninM.T.D., WalkerJ.D., JaworskaJ.S., ComberM.H.I., WattsC.D., & WorthA.P. (2003). Use of QSARs in international decision-making frameworks to predict ecologic effects and environmental fate of chemical substances. Environmental Health Perspectives111, 1376–1390.
10.
CroninM.T.D., JaworskaJ.S., WalkerJ.D., ComberM.H.I., WattsC.D., & WorthA.P. (2003). Use of QSARs in international decision-making frameworks to predict health effects of chemical substances. Environmental Health Perspectives111, 1391–1401.
11.
ECETOC (2002). Workshop on Regulatory Acceptance of (Q)SARS for Human Health and Environmental Endpoints, 4–6 March 2002, Setubal, Portugal.Brussels, Belgium: European Centre for Ecotoxicology and Toxicology of Chemicals. Website www.ecetoc.org (Accessed 11.1.05).
12.
ECETOC (1998). QSARS in the Assessment of the Environmental Fate and Effects of Chemicals. Technical Report No. 74, 142 pp. Brussels, Belgium: European Centre for Ecotoxicology and Toxicology of Chemicals.
13.
WalkerJ.D., CarlsenL., & JaworskaJ. (2003). Improving opportunities for regulatory acceptance of QSARS: the importance of model domain, uncertainty, validity and predictability. Quantitative Structure–Activity Relationships22, 346–350.
14.
JaworskaJ.S., ComberM., AuerC., & Van LeeuwenC.J. (2003). Summary of a workshop on regulatory acceptance of (Q)SARs for human health and environmental endpoints. Environmental Health Perspectives111, 1358–1360.
15.
ErikssonL., JaworskaJ., WorthA.P., CroninM.T.D., McDowellR.M., & GramaticaP. (2003). Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environmental Health Perspectives111, 1361–1375.
16.
PollackN., CunninghamA.R., KlopmanG., & RosenkranzH.S. (1999). Chemical diversity approach for evaluating mechanistic relatedness among toxicological phenomena. SAR and QSAR in Environmental Research10, 533–543.
17.
RosenkranzH.S., & CunninghamA.R. (2003). Environmental odors and health effects. Science of the Total Environment313, 15–24.
18.
PollackN., CunninghamA.R., & RosenkranzH.S. (2003). Environmental persistence of chemicals and their carcinogenic risks to humans. Mutation Research528, 81–91.
19.
ZeemanM., FairbrotherA., & GorsuchJ.W. (1995). Environmental toxicology: testing and screening. In Screening and Testing Chemicals in Commerce, Vol. OTA-BP-ENV-166, pp. 59–68. Washington, DC, USA: Congress of the United States, Office of Technology Assessment.
20.
ZeemanM. (1995). EPA's framework for ecological effects assessment. In Screening and Testing Chemicals in Commerce, Vol. OTA-BP-ENV-166, pp. 69–78. Washington, DC, USA: Congress of the United States, Office of Technology Assessment.
21.
NSTC (1999). Ecological Risk Assesssment in the Federal Government. CENR/5-99/001, 219 pp. Washington, DC, USA: Committee on Environment and Natural Resources.
22.
ICCVAM (2001). Report of the International Workshop on In Vitro Methods for Assessing Acute Systemic Toxicity. Results of an International Workshop organized by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM). NIH Publication No. 01-4499, 370 pp. Research Triangle Park, NC, USA: National Institute of Environmental Health Sciences.
23.
EkwallB., EkwallB., & SjöströmM. (2000). MEIC evaluation of acute systemic toxicity. Part VIII. Multivariate partial least squares evaluation, including the selection of a battery of cell line tests with a good prediction of human lethal peak blood concentrations for 50 chemicals. ATLA28, Suppl. 1, 201–234.
24.
HalleW. (2003). The registry of cytotoxicity: toxicity testing in cell cultures to predict acute toxicity (LD50) and to reduce testing in animals. ATLA31, 89–198.
25.
RosenkranzH.S., & CunninghamA.R. (2000). A new approach to evaluate mechanistic relationships among genotoxic phenomena: validation. Mutagenesis15, 325–328.
26.
RosenkranzH.S., & CunninghamA.R. (2001). Prevalence of mutagens in the environment: experimental data vs. simulations. Mutation Research484, 49–51.
27.
KlopmanG., & RosenkranzH.S. (1994). Prediction of carcinogenicity/mutagenicity using MULTICASE. Mutation Research305, 33–46.
28.
KlopmanG., & RosenkranzH.S. (1995). Toxicity estimation by chemical substructure analysis: the Tox II Program. Toxicology Letters79, 145–155.
29.
RosenkranzH.S., CunninghamA.R., ZhangY.P., ClaycampH.G., MacinaO.T., SussmanN.B., GrantS.G., & KlopmanG. (1999). Development, characterization and application of predictive-toxicology models. SAR and QSAR in Environmental Research10, 277–298.
30.
ZhangY.P., SussmanN., KlopmanG., & RosenkranzH.S. (1997). Development of methods to ascertain the predictivity and consistency of SAR models: application to the US National Toxicology Program rodent carcinogenicity bioassays. Quantitative Structure–Activity Relationships16, 290–295.
31.
TropshaA., GramaticaP., & GombarV.K. (2003). The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR Models. Quantitative Structure–Activity Relationships22, 69–77.
32.
ErikssonL., JohanssonE., & WoldS. (1997). QSAR model validation. In Quantitative Structure–Activity Relationships in Environmental Sciences. Proceedings of the 7th International Workshop on QSAR in Environmental Sciences, June 24–28, Elsinore, Denmark, Vol. VII (ed. ChenF., & SchüürmannG.), pp. 381–397. Pensacola, FL, USA: SETAC Press.
33.
RosenkranzM., RosenkranzH.S., & KlopmanG. (1997). Intercellular communication, tumour promotion and non-genotoxic carcinogenesis: relationships based upon structural considerations. Mutation Research381, 171–188.
34.
RosenkranzH.S., MatthewsE.J., & KlopmanG. (1992). Relationship between cellular toxicity, the maximum tolerated dose, lipophilicity and electrophilicity. ATLA20, 549–562.
35.
ZhuX., & RosenkranzH.S. (2000). Structural basis of the toxicity of chemicals in cultured human HeLa cells. ATLA28, 557–574.
36.
RosenkranzH.S., ZhangY.P., & KlopmanG. (1998). The development and characterization of a structure–activity relationship model of the Draize eye irritation test. ATLA26, 779–809.
YangW-L., KlopmanG., & RosenkranzH.S. (1992). Structural basis of the in vivo induction of micronuclei. Mutation Research272, 111–124.
40.
LabbaufA., KlopmanG., & RosenkranzH.S. (1997). Dichotomous relationship between DNA reactivity and the induction of sister chromatid exchanges in vivo and in vitro.Mutation Research377, 37–52.
41.
GomezJ., MacinaO.T., MattisonD.R., ZhangY.P., KlopmanG., & RosenkranzH.S. (1999). Structural determinants of developmental toxicity in hamsters. Teratology60, 190–205.
42.
RannugU., SjogrenM., RannugA., GillnerM., ToftgardR., GustafssonJ.A., RosenkranzH., & KlopmanG. (1991). Use of artificial intelligence in structure-affinity correlations of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) receptor ligands. Carcinogenesis12, 2007–2016.
43.
AshbyJ., & TennantR.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutation Research257, 229–306.
44.
GoldL.S., SloneT.H., & AmesB.N. (1997). Overview and update of analyses of the carcinogenic potency database. In Handbook of Carcinogenic Potency and Genotoxicity Databases (ed. GoldL.S., & ZeigerE.), pp. 661–685. Boca Raton, FL, USA: CRC Press.
45.
ZhangY.P., SussmanN., MacinaO.T., RosenkranzH.S., & KlopmanG. (1996). Prediction of the carcinogenicity of a second group of chemicals undergoing carcinogenicity testing. Environmental Health Perspectives104, 1045–1050.
46.
MacinaO.T., ZhangY.P., & RosenkranzH.S. (1998). Improved predictivity of carcinogens: the use of a battery of SAR models. In Testing, Predicting and Interpreting Carcinogenicity (ed. KitcheK.T.), pp. 227–250. New York, NY, USA: Marcel Dekker.
47.
SwenbergJ.A., ShortB., BorghoffS., StrasserJ., & CharbonneauM. (1989). The comparative pathobiology of α2μ-globulin nephropathy. Toxicology and Applied Pharmacology97, 35–46.
48.
StroblG.R., von KruedenerS., StockigtJ., GuengerichF.P., & WolffT. (1993). Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. Journal of Medicinal Chemistry36, 1136–1145.
49.
NendzaM., & RussomC.L. (1991). QSAR modelling of the ERL-D fathead minnow acute toxicity database. Xenobiotica21, 147–170.
RosenkranzH.S., & KlopmanG. (1993). Structural relationships between mutagenicity, maximum tolerated dose, and carcinogenicity in rodents. Environmental and Molecular Mutagenesis21, 193–206.
52.
TroskoJ.E., ChangC.C., UphamB., & WilsonM. (1998). Epigenetic toxicology as toxicant-induced changes in intracellular signaling leading to altered gap junctional intercellular communication. Toxicology Letters102/103, 71–78.
53.
TroskoJ.E. (1997). Challenge to the simple paradigm that “carcinogens” are “mutagens” and to the in vitro and in vivo assays used to test the paradigm. Mutation Research373, 245–249.
54.
Pet-EdwardsJ., RosenkranzH.S., ChankongV., & HaimesY.Y. (1985). Cluster analysis in predicting the carcinogenicity of chemicals using short-term assays. Mutation Research153, 167–185.
55.
TennantR.W., MargolinB.H., ShelbyM.D., ZeigerE., HasemanJ.K., SpaldingJ., CasparyW., ResnickM., StasiewiczS., AndersonB., & MinorR. (1987). Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science, New York236, 933–941.
56.
ZeigerE., HasemanJ.K., ShelbyM.D., MargolinB.H., & TennantR.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: confirmation of earlier results with 41 additional chemicals. Environmental and Molecular Mutagenesis16, Suppl. 18, 1–14.
57.
RosenkranzH.S., PollackN., & CunninghamA.R. (2000). Exploring the relationship between inhibition of gap junctional intercellular communication and other biological phenomena. Carcinogenesis21, 1007–1011.
58.
RosenkranzH.S. (2001). Allergic contact dermatitis and its relationship to carcinogenesis. Mutation Research483, 51–55.
59.
RosenkranzH.S., & CunninghamA. (2000). The high production volume chemical challenge program: the relevance of the in vivo micronucleus assay. Regulatory Toxicology and Pharmacology31, 182–189.
60.
RosenkranzH.S., & CunninghamA.R. (2000). The High Production Volume Chemical Challenge Program: the rodent LD50 and its possible replacement. ATLA28, 271–277.
61.
Environmental Protection Agency (2002). Revised Final Health Effects Test Guidelines; Acute Toxicity Testing — Background and Acute Oral Toxicity; Notice of Availability. Federal Register67, Number 241, 77,064–77,065.
62.
RosenkranzH.S., & KlopmanG. (1993). Structural relationships between mutagenicity, maximum tolerated dose, and carcinogenicity in rodents. Environmental and Molecular Mutagenesis21, 193–206.
63.
SontagJ.M., PageN.P., & SaffiottiV. (1976). Guidelines for Carcinogenicity Bioassay in Small Rodents. National Cancer Institute Carcinogenesis Technical Report Series No. 1; DHEW Publication No. NIH 76-801.Washington, DC, USA: Department of Health, Education and Welfare.
64.
ChhabraR.S., HuffJ.E., SchwetzB.S., & SelkirkJ. (1990). An overview of prechronic and chronic toxicity/carcinogenicity experimental study design and criteria used by the National Toxicology Program. Environmental Health Perspectives86, 313–321.
65.
McKenzieR., FriedM.W., SallieR., ConjeevaramH., DiBisceglieA.M., ParkY., SavareseB., KleinerD., TsokosM., LucianoC., PruettT., StotkaJ.L., StrausS.E., & HoofnagleJ.H. (1995). Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine333, 1099–1105.
66.
OlsonH., BettonG., RobinsonD., ThomasK., MonroA., KolajaG., LillyP., SandersJ., SipesG., BrackenW., BoratoM., Van DuenK., SmithP., BergerB., & HellerA. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology32, 56–67.
67.
RosenkranzH. (2001). Computational toxicology and the generation of mechanistic hypotheses: gamma-butyrolactone. SAR and QSAR in Environmental Research12, 435–444.
68.
GrantS.G., ZhangY.P., KlopmanG., & RosenkranzH.S. (2000). Modeling the mouse lymphoma forward mutational assay: the Gene-Tox Program database. Mutation Research465, 201–229.
69.
BernsteinL., GoldL.S., AmesB.N., PikeM.C., & HoelD.G. (1985). Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. Fundamental and Applied Toxicology5, 79–86.
70.
CrouchE., WilsonR., & ZeiseL. (1987). Tautology or not tautology?Journal of Toxicology and Environmental Health20, 1–10.
71.
GaylorD.W., & GoldL.S. (1995). Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. Regulatory Toxicology and Pharmacology22, 57–63.
72.
ZeiseL., CrouchE.A.C., & WilsonR. (1986). A possible relationship between toxicity and carcinogenicity. Journal of the American College of Toxicology5, 137–151.
73.
HasemanJ.K., & SeilkopS.K. (1992). An examination of the association between maximum-tolerated dose and carcinogenicity in 326 long-term studies in rats and mice. Fundamental and Applied Toxicology19, 207–213.
74.
AmesB.N., & GoldL.S. (1990). Too many rodent carcinogens: mitogenesis increases mutagenesis. Science, New York249, 970–971.
75.
Preston-MartinS., PikeM.C., RossR.K., JonesP.A., & HendersonB.E. (1990). Increased cell division as a cause of human cancer. Cancer Research50, 7415–7421.
76.
ButterworthB.E. (1990). Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutation Research239, 117–132.
77.
CohenS.M., & EllweinL.B. (1990). Cell proliferation in carcinogenesis. Science, New York249, 1007–1011.
78.
CohenS.M., & EllweinL.B. (1991). Genetic errors, cell proliferation and carcinogenesis. Cancer Research51, 6493–6505.
79.
EnneverF.K., NoonanT.J., & RosenkranzH.S. (1987). The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis2, 73–78.
80.
BartschH., & MalaveilleC. (1989). Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series. Cell Biology and Toxicology5, 115–127.
81.
ShelbyM.D. (1988). The genetic toxicity of human carcinogens and its implications. Mutation Research204, 3–15.
82.
AshbyJ., & MorrodR.S. (1991). Detection of human carcinogens. Nature, London352, 185–186.
83.
LucierG.W. (1992). Receptor-mediated carcinogenesis. In Mechanisms of Carcinogenesis in Risk Identification (ed. VainioP.N.M.H., McGregorD.B., & McMichaelO.J.), pp. 87–112. Lyon, France: International Agency for Research on Cancer.
84.
RosenkranzH.S., KlopmanG., ZhangS.Y., GrahamC., & KarolM.H. (1999). Relationship between allergic contact dermatitis and electrophilicity. Environmental Health Perspectives107, 129–132.
85.
ChankongV., HaimesY.Y., RosenkranzH.S., & Pet-EdwardsJ. (1985). The carcinogenicity prediction and battery selection (CPBS) method: a Bayesian approach. Mutation Research153, 135–166.
